{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:02:06Z","timestamp":1767844926976,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T00:00:00Z","timestamp":1188345600000},"content-version":"vor","delay-in-days":89,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:p><jats:bold><jats:sc>abstract<\/jats:sc>:\u2002<\/jats:bold>  <jats:bold>As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer\u2010associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune\u2010suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age\u2010 and sex\u2010matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer\u2010associated morbidity. Patients were 47 (20\u201373) years old at the onset of malignancy, which appeared 13 (1\u201345) years later than SLE. Cancer prevalence was the highest in the first 5\u201310 years of lupus. Breast cancer was the most common malignancy (<jats:italic>n<\/jats:italic>= 11) followed by gastrointestinal tumors (<jats:italic>n<\/jats:italic>= 9), cervix cancer and hematologic malignancies (<jats:italic>n<\/jats:italic>= 5 for both), bronchial cancer (<jats:italic>n<\/jats:italic>= 4), bladder, skin, and ovarian cancer (<jats:italic>n<\/jats:italic>= 1 for each). Standardized incidence ratio was the highest for non\u2010Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4\u201312.5) and cervix cancer (SIR 1.7, 95%CI 0.6\u20134.1). Although 76% of patients with cancer received immune\u2010suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer\u2010related. As such the cancer\u2010associated mortality was 11% (18\/164). This peaked during the last 4 years of the study period (8\/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.<\/jats:bold> <\/jats:p>","DOI":"10.1196\/annals.1422.008","type":"journal-article","created":{"date-parts":[[2007,10,16]],"date-time":"2007-10-16T22:43:07Z","timestamp":1192574587000},"page":"76-82","source":"Crossref","is-referenced-by-count":47,"title":["Occurrence of Malignancies in Hungarian Patients with Systemic Lupus Erythematosus"],"prefix":"10.1111","volume":"1108","author":[{"given":"T\u00dcNDE","family":"TARR","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BAL\u00c1ZS","family":"GYORFY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9VA","family":"SZEKANECZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HARJIT PAL","family":"BHATTOA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARGIT","family":"ZEHER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GYULA","family":"SZEGEDI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EMESE","family":"KISS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21955"},{"key":"e_1_2_6_3_2","first-page":"171","article-title":"Systemic lupus erythematosus survival in Hungary","volume":"17","author":"Kiss E.","year":"1999","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.03.007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/annonc\/mdf127","article-title":"Cancer prevalence in European registry areas","volume":"13","author":"Micheli A.","journal-title":"Ann. Oncol."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2337"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21458"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_6_10_2","first-page":"302","volume-title":"Statistical Methods in Cancer Research. Vol. II. The Design and Analysis of Cohort Studies","author":"Breslow N.E.","year":"1987"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000209423.39033.94"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21029"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400424"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740252937568"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678416079"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.10.1147"},{"key":"e_1_2_6_17_2","first-page":"217","article-title":"Increased risk of malignancy in patients with systemic lupus erythematosus","volume":"46","author":"Ramsey\u2010Goldman R.","year":"1998","journal-title":"J. Invest. Med."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120301678646128"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh643"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1422.008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1422.008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T03:04:49Z","timestamp":1695697489000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1422.008"}},"subtitle":["Results from a Single Center"],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1196\/annals.1422.008"],"URL":"https:\/\/doi.org\/10.1196\/annals.1422.008","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}